BIIB250110C170000
- 0.05
- 0.000.00%
Biogen Newsroom
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)'s Struggles With Alzheimer's and MS Challenges?
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities
Biogen Is Maintained at Buy by Truist Securities
Biogen Analyst Ratings
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $220
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
HealthTech Business Organisation Study: How to Organize Digital Health Businesses, Especially at Large Pharma and MedTech Companies - ResearchAndMarkets.com
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231
RBC Cuts Price Target on Biogen to $231 From $260, Keeps Outperform Rating
Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today